United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,512.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $235.42, for a total transaction of $847,512.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,604.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Up 1.1 %

UTHR stock opened at $235.08 on Tuesday. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company has a market cap of $11.06 billion, a price-to-earnings ratio of 11.85 and a beta of 0.52. The company has a 50 day moving average of $229.87 and a two-hundred day moving average of $228.29.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. During the same quarter in the prior year, the firm earned $2.67 EPS. The company’s revenue was up 25.1% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Co. will post 23.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on UTHR. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, SVB Leerink assumed coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $292.67.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. raised its holdings in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares in the last quarter. Formidable Asset Management LLC raised its holdings in shares of United Therapeutics by 1.5% during the 3rd quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company’s stock valued at $821,000 after purchasing an additional 53 shares in the last quarter. Alaska Permanent Fund Corp raised its holdings in shares of United Therapeutics by 1.7% during the 3rd quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company’s stock valued at $752,000 after purchasing an additional 57 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of United Therapeutics by 1.6% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after purchasing an additional 61 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in shares of United Therapeutics by 0.5% during the 1st quarter. Federated Hermes Inc. now owns 13,603 shares of the biotechnology company’s stock valued at $2,441,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.